Flying The Web For News.
  • Epiphany
    Epiphany
  • Career Exam Study
    Career Exam Study
  • 2024 Presidential Election
    2024 Presidential Election
  • E-commerce Guide
    E-commerce Guide
  • Dropshipping Guide
    Dropshipping Guide
  • Microsoft Exam
    Microsoft Exam
  • IT Career News
    IT Career News
+ Larger Font | - Smaller Font
Share

Globe NewsWire News Distribution Service

Press Release: Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging

Details
Category: Globe NewsWire News Distribution Service

MELBOURNE, Australia and INDIANAPOLIS, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has submitted its Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX250-CDx (Zircaix®1, 89Zr- girentuximab) kidney cancer imaging2.


Posted: 2024-12-29 21:53:00

Get Full News Story On GlobeNewsWire Press Release Service



Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.

Tags

press | release | telix | files | zircaix®


Related News Stories From The Web And More

Related Bing News Search Results

Press Release: Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging - Newscast

Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging

Sun, 29 Dec 2024 22:00:00 GMT MELBOURNE, Australia and INDIANAPOLIS, Dec. 30, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has submitted its Biologics ...

Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging

Sun, 29 Dec 2024 13:55:00 GMT Telix, the Company) today announces that it has submitted its Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX250-CDx (Zircaix®1, ...

Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging

Sun, 29 Dec 2024 08:53:00 GMT Telix continues to target a full U.S. commercial launch in 2025 addressing a major unmet medical need for patients with suspected ccRCC.” About TLX250-CDx TLX250-CDx (Zircaix® 1) is an ...

Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging

Sun, 29 Dec 2024 05:53:00 GMT MELBOURNE, Australia and INDIANAPOLIS, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has submitted its ...

Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging

Sat, 28 Dec 2024 15:59:00 GMT Telix, the Company) today announces that it has submitted its Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX250-CDx (Zircaix®[1], 89 Zr ...


Blow Us A Whistle